Literature DB >> 23147034

Determination of voriconazole in human plasma by HPLC-ESI-MS and application to pharmacokinetic study.

Dai Lin1, Guoliang Li, Lingyun Chen.   

Abstract

A fast, sensitive, high-performance liquid chromatography-tandem mass spectrometry method was developed for the determination of voriconazole in human plasma. Carbamazepine was used as the internal standard and the sample pretreatment involved one-step protein precipitation. Chromatographic separation was conducted on an Ultimate C18 column with a mobile phase consisting of acetonitrile-water (containing 0.1% formic acid; 40:60, v/v) at a flow rate of 0.3 mL/min. The detection of voriconazole was performed on a triple-quadrupole tandem mass spectrometer by multiple reaction monitoring with an electrospray ionization source in the positive mode. The standard curve was linear (r(2) ≥ 0.99) within the concentration range of 2.49-293 ng/mL. The intra-day and inter-day precision values were below 5.3%, and the accuracy was within -4.3-5.7%. The method was applicable to the clinical study of the pharmacokinetics of voriconazole in healthy volunteers following oral administration.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23147034     DOI: 10.1093/chromsci/bms178

Source DB:  PubMed          Journal:  J Chromatogr Sci        ISSN: 0021-9665            Impact factor:   1.618


  3 in total

Review 1.  Pediatric Clinical Pharmacology of Voriconazole: Role of Pharmacokinetic/Pharmacodynamic Modeling in Pharmacotherapy.

Authors:  Rajendra S Kadam; Johannes N Van Den Anker
Journal:  Clin Pharmacokinet       Date:  2016-09       Impact factor: 6.447

Review 2.  Review of Chromatographic Methods Coupled with Modern Detection Techniques Applied in the Therapeutic Drugs Monitoring (TDM).

Authors:  Tomasz Tuzimski; Anna Petruczynik
Journal:  Molecules       Date:  2020-09-03       Impact factor: 4.411

Review 3.  Assessment of greenness for the determination of voriconazole in reported analytical methods.

Authors:  Hemanth Kumar Chanduluru; Abimanyu Sugumaran
Journal:  RSC Adv       Date:  2022-02-28       Impact factor: 3.361

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.